MedTrace Logo

Evaluation of KX2-391 in Patients With Advanced Malignancies

NCT00658970 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-06-08

No results posted yet for this study

Summary

The purpose of this Phase 1 study is to determine the safety and tolerability of KX2-391 in cancer patients.

Conditions

Interventions

DRUG

KX2-391

2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops

Sponsors & Collaborators

  • Athenex, Inc.

    lead INDUSTRY

Principal Investigators

  • Aung Naing, M.D. · M.D. Anderson Cancer Center

  • Roger B Cohen, M.D. · Fox Chase Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-03-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00658970 on ClinicalTrials.gov